Clinical and genetic characteristics of hereditary pancreatitis in Europe
Nathan Howes(University of Liverpool), John P. Neoptolemos(University of Liverpool), Deborah Stocken(Cancer Research UK Clinical Trials Unit), Generoso Uomo(Ospedale Antonio Cardarelli), William Greenhalf(University of Liverpool), Julius Špičák(Institute of Clinical and Experimental Medicine), Richard Charnley(Newcastle upon Tyne Hospitals NHS Foundation Trust), Jan B.�M.�J. Jansen(Radboud University Nijmegen), Kaspar Truninger(University College Dublin), Ian O. Ellis(University of Nottingham), Brendan Drumm(University College Dublin), Giorgio Cavallini(University of Verona), Markus M. Lerch(Ludwig-Maximilians-Universität München), Péter Simon(Universität Greifswald), Miriam Delhaye(Université Libre de Bruxelles), R Ammann(University College Dublin), Roger Mountford(University of Liverpool), David C. Whitcomb(Christian Medical College & Hospital)
Cited by 615
Related Papers
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
|The Lancet|2017|1.9k
Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene
|Nature Genetics|1996|1.6k
Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection
|JAMA|2010|1.4k
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
|The Lancet Oncology|2019|1.2k
Chronic pancreatitis: Diagnosis, classification, and new genetic developments
|Gastroenterology|2001|1.2k